The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity

Clin Infect Dis. 2022 Mar 9;74(5):897-900. doi: 10.1093/cid/ciab543.

Abstract

Little is known about severe acute respiratory syndrome coronavirus 2 "vaccine-breakthrough" infections (VBIs). Here we characterize 24 VBIs in predominantly young healthy persons. While none required hospitalization, a proportion endorsed severe symptoms and shed live virus as high as 4.13 × 103 plaque-forming units/mL. Infecting genotypes included both variant-of-concern (VOC) and non-VOC strains.

Keywords: SARS-CoV-2; live virus; patient-reported outcomes; symptoms; vaccine breakthrough.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Genetic Variation
  • Humans
  • Phenotype
  • RNA, Messenger
  • SARS-CoV-2* / genetics
  • Vaccines, Synthetic
  • Virus Shedding
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic
  • mRNA Vaccines